Can a Weight-Loss drug tame PCOS hormones?

NCT ID NCT07747909

Recruiting now Disease control Sponsor: Khyber Medical University Peshawar Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests whether orlistat, a weight-loss medication, can improve hormonal and metabolic features in women with polycystic ovary syndrome (PCOS). Women aged 18-45 with PCOS will receive either orlistat or a placebo, alongside standard lifestyle advice, for three months. The study measures changes in hormones, blood sugar, cholesterol, liver function, and quality of life to see if orlistat offers added benefits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: orlistat
What this could lead to: If effective, orlistat could become a helpful add-on to lifestyle changes for managing PCOS symptoms like hormonal imbalance and metabolic issues.
What could go wrong: This is a relatively small, short-term trial, and results may not apply to all women with PCOS. Orlistat can cause gastrointestinal side effects, and its benefit over lifestyle changes alone is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYSTIC OVARY SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLYCYSTIC OVARY SYNDROME

Contacts and locations

Locations

Ayub Teaching Hospital
RECRUITING

Abbottābād, Khyber Pakhtunkhwa, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.